Please login to the form below

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

Bristol-Myers Squibb is also testing its own PD-1 inhibitor Opdivo (nivolumab) in this indication, with a trial currently in phase 2.

MSD’s Keytruda catches up in kidney cancer

Keytruda is continuing to prove its lead in the anti-PD-1/PD-L1 therapy area, with this approval closely following its FDA approval in advanced RCC earlier this year. ... BMS’ anti-PD-1 therapy is only approved for patients with intermediate- and
'Therapeutic overcrowding' could hit big pharma returns

Exhibit A in their analysis is the six PD-1/PD-L1 checkpoint inhibitor drugs already on the market, with new entrants still to come from Asian companies, that are predicted
GSK to develop Ionis hepatitis B drugs

This is led by GS-9688, a toll like receptor (TLR-8) agonist currently in phase 2, with a PD-L1 therapy in phase 1, GS-4224.
BeiGene gets speedy US review for lymphoma drug zanubrutinib

The MCL filing is based on data from a phase 1/2 trial of BeiGene’s BTK inhibitor in patients with B-cell lymphomas, as well as an aggregate of 123 ... In addition to zanubrutinib, BeiGene is also developing PD-1 inhibitor tislelizumab – which has
AZ’s Imfinzi combo bombs again in non-small cell lung cancer

The NEPTUNE study compared PD-L1 inhibitor Imfinzi (durvalumab) and AZs experimental CTLA4 inhibitor tremelimumab to standard platinum-based chemotherapy in previously-untreated patients with advanced NSCLC. ... The readout will also be a concern to

More from news
Approximately 23 fully matching, plus 300 partially matching documents found.

2019: CRISPR and therapeutic gene editing comes of age

The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the ... hope was that - without the brake of PD-1 – the edited cells
Immuno-oncology in 2019: the rapid evolution continues

However this class of drugs aren’t miracle cures: many patients and tumour types do not respond to PD-1/PD-L1s – the overall response rate (ORR) is commonly well below ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
Drug launches to watch in 2019

9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers
Is China ready for a pharmaceutical gold rush?

The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.
Combined immunotherapies – potential and pitfalls

We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... There are a variety of strategies attempting to overcome intrinsic resistance to

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Crescendo Biologics appoints Dr Kevin Johnson as chairman

Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as ... 1 Humabodies.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Oncosec

with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

patients whose disease was truly refractory to anti–PD-1 antibody monotherapy.17. ... Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into
Immuno-oncology: The market opportunity for PD-1/PD-L1s

Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.
How pembrolizumab will change the management of advanced lung cancer

The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) ... In light of these findings, it is
A stumble, but not a fall – what’s next for Opdivo?

Until things took a turn for the worse. . Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.